Synovial sarcoma diagnosis and management in the era of targeted therapies

Current Opinion in Oncology

Volumn 27, Issue 4, 2015, Pages 316-322

  Vlenterie, Myrella ^a   Jones, Robin L ^b   Van Der Graaf, Winette T A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Current treatment; Diagnostics; Synovial sarcoma; Targeted therapies

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN TYROSINE KINASE;

CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER THERAPY; EXPERIMENTAL THERAPY; HUMAN; MULTIMODALITY CANCER THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SYNOVIAL SARCOMA; ADULT; AGED; ANTAGONISTS AND INHIBITORS; GENETICS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROGNOSIS; SARCOMA, SYNOVIAL; YOUNG ADULT;

ADULT; AGED; HUMANS; MOLECULAR TARGETED THERAPY; PROGNOSIS; RECEPTOR PROTEIN-TYROSINE KINASES; SARCOMA, SYNOVIAL; YOUNG ADULT;

EID: 84959071436     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000198     Document Type: Review

References (60)

1. Corey RM, Swett K, Ward WG. Epidemiology and survivorship of soft tissue sarcomas in adults: a national cancer database report. Cancer Med 2014; 3:1404-1415.
2. Kose D, Annagur A, Erol C, et al. Synovial sarcoma in a premature newborn. Pediatr Int 2014; 56:e17-e20.
3. Vlenterie M, Ho VKY, Kaal SEJ, et al. Age as independent prognostic factor for survival of localised synovial sarcoma. Abstract paper 022 presented at CTOS; 17 October, 2014; Berlin, Germany.
4. Palmerini E, Staals EL, Alberghini M, et al. Synovial sarcoma: retrospective analysis of 250 patients treated at a single institution. Cancer 2009; 115:2988-2998.
5. Ladanyi M, Antonescu CR, Leung DH, et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multiinstitutional retrospective study of 243 patients. Cancer Res 2002; 62:135-140.
6. Sultan I, Rodriguez-Galindo C, Saab R, et al. Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology, and End Results program, 1983 to 2005: an analysis of 1268 patients. Cancer 2009; 115: 3537-3547.
7. Lewis JJ, Antonescu CR, Leung DH, et al. Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J Clin Oncol 2000; 18:2087-2094.
8. Krieg AH, Hefti F, Speth BM, et al. Synovial sarcomas usually metastasize after 5 years: a multicenter retrospective analysis with minimum follow-up of 10 years for survivors. Ann Oncol 2011; 22:458-467.
9. Panagopoulos I, Mertens F, Isaksson M, et al. Clinical impact of molecular and cytogenetic findings in synovial sarcoma. Genes Chromosomes Cancer 2001; 31:362-372.
10. Kadoch C, Crabtree GR. Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma. Cell 2013; 153:71-85.
11. Guadagnolo BA, Zagars GK, Ballo MT, et al. Long-term outcomes for synovial sarcoma treated with conservation surgery and radiotherapy. Int J Rad Oncol Biol Phys 2007; 69:1173-1180.
12. Canter RJ, Qin LX, Maki RG, et al. A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients. Clin Cancer Res 2008; 14:8191-8197.
13. Guillou L, Benhattar J, Bonichon F, et al. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J Clin Oncol 2004; 22: 4040-4050.
14. Ren T, Lu Q, Guo W, et al. The clinical implication of SS18-SSX fusion gene in synovial sarcoma. Br J Cancer 2013; 109:2279-2285.
15. Lagarde P, Przybyl J, Brulard C, et al. Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas. J Clin Oncol 2013; 31:608-615.
16. Chakiba C, Lagarde P, Pissaloux D, et al. Response to chemotherapy is not related to chromosome instability in synovial sarcoma. Ann Oncol 2014; 25:2267-2271.
17. Przybyl J, Sciot R, Wozniak A, et al. Metastatic potential is determined early in synovial sarcoma development and reflected by tumor molecular features. Int J Biochem Cell Biol 2014; 53:505-513.
18. Demir D, Yaman B, Anacak Y, et al. Prognostic significance of Bcl-2, c-myc, survivin and tumor grade in synovial sarcoma. Turk Patoloji Derg 2014; 30: 55-65.
19. Taubert H, Heidenreich C, Holzhausen HJ, et al. Expression of survivin detected by immunohistochemistry in the cytoplasm and in the nucleus is associated with prognosis of leiomyosarcoma and synovial sarcoma patients. BMC Cancer 2010; 10:65.
20. Charbonneau B, Vogel RI, Manivel JC, et al. Expression of FGFR3 and FGFR4 and clinical risk factors associated with progression-free survival in synovial sarcoma. Hum Pathol 2013; 44:1918-1926.
21. Suehara Y, Tochigi N, Kubota D, et al. Secernin-1 as a novel prognostic biomarker candidate of synovial sarcoma revealed by proteomics. J Proteomics 2011; 74:829-842.
22. Palmerini E, Benassi M, Quattrini I, et al. Prognostic and predictive role of CXCR4, IGF-1R and Ezrin expression in localized synovial sarcoma: is chemotaxis important to tumor response? Orphanet J Rare Dis 2015; 10:6.
23. Tarkan Y, Erkan A, Selcuk ES, et al. Clinical and pathological features of patients with resected synovial sarcoma: a multicenter retrospective analysis of the Anatolian Society of Medical Oncology. J Cancer Res Ther 2014; 10:73-78.
24. Chinen LT, Mello CA, Abdallah EA, et al. Isolation, detection, and immunomorphological characterization of circulating tumor cells (CTCs) from patients with different types of sarcoma using isolation by size of tumor cells: a window on sarcoma-cell invasion. OncoTargets Ther 2014; 7:1609-1617.
25. Sherman KL, Wayne JD, Chung J, et al. Assessment of multimodality therapy use for extremity sarcoma in the United States. J Surg Oncol 2014; 109:395-404.
26. Schwindenhammer B, Podleska LE, Kutritz A, et al. The pathologic response of resected synovial sarcomas to hyperthermic isolated limb perfusion with melphalan and TNF-Alpha: a comparison with the whole group of resected soft tissue sarcomas. World J Surg Oncol 2013; 11:185.
27. Song S, Park J, Kim HJ, et al. Effects of adjuvant radiotherapy in patients with synovial sarcoma. Am J Clin Oncol 2014. [Epub ahead of print]
28. Naing KW, Monjazeb AM, Li CS, et al. Perioperative radiotherapy is associated with improved survival among patients with synovial sarcoma: a SEER analysis. J Surg Oncol 2014; 111:158-164.
29. Brennan B, Stevens M, Kelsey A, Stiller CA. Synovial sarcoma in childhood and adolescence: a retrospective series of 77 patients registered by the Children's Cancer and Leukaemia Group between 1991 and 2006. Pediatr Blood Cancer 2010; 55:85-90.
30. Ferrari A, De Salvo GL, Brennan B, et al. Synovial sarcoma in children and adolescents: the European Pediatric Soft Tissue Sarcoma Study Group prospective trial (EpSSG NRSTS 2005). Ann Oncol 2015; 26:567-572.
31. The ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25 (Suppl 3):iii102-iii112.
32. Eilber FC, Brennan MF, Eilber FR, et al. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Ann Surg 2007; 246:105-113.
33. Italiano A, Penel N, Robin YM, et al. Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group. Ann Oncol 2009; 20:425-430.
34. Sleijfer S, Ouali M, van Glabbeke M, et al. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer 2010; 46:72-83.
35. van der Graaf WT, Elisa R, Gronchi A, et al. on behalf of the EORTC Soft Tissue and Bone Sarcoma Group. Outcome of chemotherapy in synovial sarcoma patients: review of 15 clinical trials from EORTC involving advanced SyS compared to other soft tissue sarcoma. Abstract paper 024 presented at CTOS; 17 October, 2014; Berlin, Germany.
36. Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol 2014; 15:415-423.
37. Salah S, Yaser S, Salem A, et al. Factors influencing survival in metastatic synovial sarcoma: importance of patterns of metastases and the first-line chemotherapy regimen. Med Oncol 2013; 30:639.
38. Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009; 27:3126-3132.
39. van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic softtissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; 379:1879-1886.
40. Le Cesne A, Cresta S, Maki RG, et al. A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. Eur J Cancer 2012; 48:3036-3044.
41. Yetisyigit T, Arpaci E, Seber ES, et al. Salvage treatment experience in advanced synovial sarcoma: a multicenter retrospective analysis of the Anatolian Society of Medical Oncology. Asian Pac J Cancer Prev 2013; 14:5185-5188.
42. Mita MM, Natale RB, Wolin EM, et al. Pharmacokinetic study of aldoxorubicin in patients with solid tumors. Investig New Drugs 2014; 33:341-348.
43. Nielsen TO, Poulin NM, Ladanyi M. Synovial sarcoma: recent discoveries as a roadmap to new avenues for therapy. Cancer Discovery 2015; 5:124-134.
44. Hong DS, Garrido-Laguna I, Ekmekcioglu S, et al. Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. Cancer 2014; 120:2164-2173.
45. Fox E, Aplenc R, Bagatell R, et al. A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. J Clin Oncol 2010; 28:5174-5181.
46. Maki RG, D'Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009; 27:3133-3140.
47. George S, Merriam P, Maki RG, et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 2009; 27:3154-3160.
48. Eberst L, Cropet C, Le Cesne A, et al. The off-label use of targeted therapies in sarcomas: the OUTC'S program. BMC Cancer 2014; 14:870.
49. Chugh R, Wathen JK, Maki RG, et al. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol 2009; 27:3148-3153.
50. Pappo AS, Vassal G, Crowley JJ, et al. A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study. Cancer 2014; 120: 2448-2456.
51. Olmos D, Postel-Vinay S, Molife LR, et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol 2010; 11:129-135.
52. Schoffski P, Adkins D, Blay JY, et al. An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours. Eur J Cancer 2013; 49:3219-3228.
53. Ray-Coquard I, Le Cesne A, Whelan JS, et al. A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens. Oncologist 2008; 13:467-473.
54. Maki RG, Jungbluth AA, Gnjatic S, et al. A pilot study of anti-CTLA4 antibody ipilimumab in patients with synovial sarcoma. Sarcoma 2013; 2013:168145.
55. Pollack SM, Loggers ET, Rodler ET, et al. Immune-based therapies for sarcoma. Sarcoma 2011; 2011:438940.
56. Kawaguchi S, Tsukahara T, Ida K, et al. SYT-SSX breakpoint peptide vaccines in patients with synovial sarcoma: a study from the Japanese Musculoskeletal Oncology Group. Cancer Sci 2012; 103:1625-1630.
57. Robbins PF, Kassim SH, Tran TL, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T cell receptor: long term follow up and correlates with response. Clin Cancer Res 2015; 21:1019-1027.
58. Nagayama S, Fukukawa C, Katagiri T, et al. Therapeutic potential of antibodies against FZD 10, a cell-surface protein, for synovial sarcomas. Oncogene 2005; 24:6201-6212.
59. Fukukawa C, Nagayama S, Tsunoda T, et al. Activation of the noncanonical Dvl-Rac1-JNK pathway by frizzled homologue 10 in human synovial sarcoma. Oncogene 2009; 28:1110-1120.
60. Fukukawa C, Hanaoka H, Nagayama S, et al. Radioimmunotherapy of human synovial sarcoma using a monoclonal antibody against FZD10. Cancer Sci 2008; 99:432-440.